Results 161 to 170 of about 108,375,652 (210)

The Involvement of the Peptidergic Systems in Breast Cancer Development. [PDF]

Cancers (Basel)
Sánchez ML, Robinson P, Italia Z, Hoang T, Muñoz M, Coveñas R.   +5 more
europepmc   +1 more source

Beyond Medicalization: Menopause Care with Empathy: An Editorial Review. [PDF]

J Midlife Health
Sharma S, Mehra R.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Safety of neurokinin-1 receptor antagonists

Expert Opinion on Drug Safety, 2013
The substance P (SP)/neurokinin (NK)-1 receptor system is involved in many pathological processes. NK-1 receptor antagonists have many promising therapeutic indications. However, the only NK-1 receptor antagonist used in clinical practice is the drug aprepitant and its intravenously administered prodrug, fosaprepitant.
Miguel, Muñoz, Rafael, Coveñas
openaire   +2 more sources

A selective and extremely potent antagonist of the neurokinin-1 receptor

Brain Research, 1992
Sendide [Tyr6,D-Phe7,D-His9]-substance P(6-11) has been examined by measurements of ligand binding to crude membrane fractions and by functional tests on the spinally mediated behavioral response. Sendide potently displaced [3H]-labeled substance P (SP) binding to mouse spinal cord membranes in a competitive manner.
T, Sakurada, Y, Manome, K, Tan-No, S, Sakurada, K, Kisara, M, Ohba, L, Terenius   +6 more
openaire   +3 more sources

Neurokinin-1 receptor antagonists: a comprehensive patent survey

Expert Opinion on Therapeutic Patents, 2010
Substance P is involved in mediating a number of biological effects such as emesis, pain, inflammation, bronchoconstriction, antitumor activity, and regulation of gastrointestinal and CNS function by binding to the neurokinin-1 (NK1) receptor. Antagonists of this receptor have the potential to be useful in the treatment of various disease conditions ...
Shih-Chung, Huang, Vijaya L, Korlipara
openaire   +2 more sources

Neurokinin-1 receptor antagonist SR140333

NeuroReport, 1997
Substance P (SP) has been implicated in immune responses and could increase glutamate release, and inflammatory reactions are known to be able to potentiate ischemic damage. We have previously found that SP was over-expressed in cerebral ischemia and speculated that SP may play a role in exacerbating ischemic damage.
Z, Yu, G, Cheng, X, Huang, K, Li, X, Cao
openaire   +2 more sources

Potential therapeutic targets for neurokinin-1 receptor antagonists

Expert Opinion on Emerging Drugs, 2004
The peptide substance P and its tachykinin receptor, neurokinin-1 (NK1), have been the focus of considerable research for their role in a variety of both central and peripheral diseases. Recent preclinical data, as well as relevant clinical findings, support the potential therapeutic value of NK1 receptor antagonists in centrally mediated disease ...
openaire   +2 more sources

The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists

Peptides, 2012
The last decades have seen no significant progress in extending the survival of lung cancer patients and there is an urgent need to improve current therapies. The substance P (SP)/neurokinin-1 receptor (NK-1R) system plays an important role in the development of cancer: SP and NK-1R antagonists respectively induce cell proliferation and inhibition in ...
Miguel, Muñoz, Ana, González-Ortega, Marisa, Rosso, María José, Robles-Frias, Andres, Carranza, Manuel Vicente, Salinas-Martín, Rafael, Coveñas   +6 more
openaire   +2 more sources

Multivalently binding antagonists for the neurokinin-1 receptor

2020
The goal of this thesis was to investigate the neurokinin-1 receptor (NK1R) as a potential target site for multivalent receptor blockade. Since the NK1R is peripherally expressed on various cell types of the human body and its expression increases when an immune response occurs, this receptor seems to offer great potential for selective and specific ...
openaire   +1 more source

Antagonists that demonstrate species differences in neurokinin-1 receptors.

Molecular Pharmacology, 1992
125I-Bolton-Hunter-substance P (125I-BH-SP) binding properties of three novel classes of neurokinin-1 (NK-1) receptor antagonists were investigated in tissues derived from humans, guinea pigs, and rats. 125I-BH-SP was shown to bind to a single class of binding sites, with similar dissociation constants, Kd, in human astrocytoma cells (U-373 MG), human ...
K C, Appell, B J, Fragale, J, Loscig, S, Singh, B E, Tomczuk   +4 more
openaire   +2 more sources